Objective: Lennox-Gastaut syndrome (LGS) is a drug-resistant, childhood onset electroclinical epilepsy syndrome with multiple seizure types and diagnostic electroencephalogram findings. ZX008 (fenfluramine HCl oral solution) was well tolerated and reduced seizure frequency in Dravet syndrome, prompting this phase 2, open-label, dose-finding study of add-on ZX008 in patients with LGS (NCT02655198). Methods: Eligible treatment-refractory patients with LGS aged 3-18 years with ≥4 documented convulsive seizures (CS) in the prior 4 weeks were administered adjunctive ZX008 twice daily at an initial dose of 0.2 mg/kg/d, with incremental dose escalations up to 0.8 mg/kg/d or 30 mg/d (maximum dose) every 4 weeks in nonresponders (<50% reduction in CS frequency). After 20 weeks (core study), responders were offered entry into a long-term extension study. Seizures were captured via diary. Cardiac safety was monitored by Doppler echocardiography and electrocardiogram. Results: Thirteen patients were enrolled (mean age = 11.7 years, range = 3-17).
| INTRODUCTION
Lennox-Gastaut syndrome (LGS) is one of the most difficult childhood-onset epileptic encephalopathies to manage. Age of onset is usually between 2 and 6 years, and diagnosis requires a triad of defining features: moderateto-severe cognitive impairment; abnormal electroencephalogram, with diffuse slow spike and wave interictal complexes while awake and fast rhythmic bursts while asleep; and multiple seizure types. The most common seizure types are tonic or atonic seizures ("drop attacks") and atypical absences; other seizure types may include myoclonic, generalized tonic-clonic, and focal onset seizures, as well as status epilepticus and nonconvulsive status. [1] [2] [3] [4] Patients with LGS rarely achieve complete seizure control despite available treatment options approved by the United States Food and Drug Administration and European Medicines Agency. Achieving a reduction in seizure frequency usually requires polypharmacy with an individualized regimen. 1 Valproic acid is the standard first-line treatment; add-on topiramate, lamotrigine, or rufinamide are common second-line choices. Other options include felbamate, clobazam, vagus nerve stimulation (VNS), and ketogenic diet as add-on therapy. Emergency benzodiazepines are recommended for rescue usage. 2, [4] [5] [6] Better treatment options are an urgent unmet need among the LGS patient community and their caregivers. An oral solution of fenfluramine HCl (ZX008; Zogenix, Inc., Emeryville, California) was granted orphan drug status by the United States and European Union for the adjunctive treatment of patients with LGS and Dravet syndrome (DS), another pharmacoresistant pediatric form of epilepsy; it was also designated by United States Food and Drug Administration as breakthrough therapy for DS. 7, 8 Studies have demonstrated sustained efficacy with add-on fenfluramine treatment in seizure reduction for patients with DS, including a phase 3 trial. [7] [8] [9] [10] [11] [12] Fenfluramine's antiepileptic activity is thought to arise from agonist activity of neuronally released serotonin (5-HT) or via a direct agonist effect on 5-HT receptors (5HT1D and 5HT2C). Additionally, fenfluramine has been shown to have effects on sigma 1 receptors, which have been implicated as having a role in epilepsy. [13] [14] [15] Fenfluramine was previously prescribed as an anorexigen until 1997, when it was withdrawn from human use after reports of increased risk of cardiac valvulopathy and pulmonary hypertension in adult patients treated for obesity. 11, 16 Unlike its previous history in adult obese patients, however, the benefit/risk ratio profile of lowdose fenfluramine treatment in patients with DS appears to be positive in that recently reported phase 3 results showed a profound reduction in seizure frequency with subjects in the ZX008 0.8-mg/kg/d treatment group, who experienced a 63.9% greater reduction in monthly frequency of convulsive seizures (CS; primary end point). Furthermore, no clinical or echocardiographic observations of cardiac valvulopathy or pulmonary hypertension have been reported in a recently completed phase 3 study or with long-term use in Belgium. [7] [8] [9] 12 The purpose of this phase 2, pilot, dose-finding study was to evaluate the safety and effectiveness of ZX008 as an adjunctive treatment option for pediatric patients with LGS in a small prospective cohort of patients at 20 weeks (core study), and to assess longer-term durability of effect at 15 months (extension study).
| MATERIALS AND METHODS

| Patients
Patients were recruited from childhood epilepsy clinics in Leuven and Antwerp. Eligible participants were male or female patients aged 3-18 years who were diagnosed with LGS per the International League Against Epilepsy's published diagnostic description, had failed multiple antiepileptic therapies, had ≥4 documented CS (generalized tonic-clonic, tonic, atonic, and focal with a clearly recognized motor component) in the prior 4 weeks, and were receiving ≥2 antiepileptic therapies at stable doses in the 4 weeks prior to enrollment. 
Key Points
• Twice-daily oral ZX008 (fenfluramine HCl) was an effective, durable add-on treatment in a small cohort of patients with LGS (N = 13) • ZX008 administration to 20 weeks provided ≥50% reduction in CS frequency in 62% of patients and ≥75% reduction in 23% of patients (median reduction = 53%, N = 13) • After 15 months of ZX008, median reduction in CS frequency was 58% (n = 9), with 67% of patients achieving ≥50% reduction and 33% of patients achieving ≥75% reduction • Adverse events included decreased appetite and decreased alertness with no echocardiographic signs of cardiac valvulopathy or pulmonary hypertension (NCT02655198) was divided into two parts: a core study (20 weeks) . At the end of the core study, responders were offered entry into a long-term extension study. Seizure frequencies were determined by seizure diaries at 4-week intervals (core study) and in the 28 days prior to each 3-month study visit (extension study). Patients continued into the extension study if they were responders with decreased seizure frequency or by parental request. During the core study, concomitant antiepileptic therapies remained unchanged, but changes were allowed in the extension study. Adverse events (AEs) were assessed at each study visit during both the core and extension studies. Cardiovascular safety was assessed via echocardiogram assessments at baseline and end of the core study, then every 3 months at the discretion of the investigator in the extension study (but at least once per year).
| Study end points
The primary study end point was the number of responders at each study visit, defined as ≥50% CS reduction from baseline. Secondary end points included AEs and change in seizure frequency per patient. Data were expressed as mean ± SD, medians, ranges, and percentages.
| Study drug
ZX008 was obtained from Zogenix, and was manufactured, packaged, and distributed by PCI Pharma Services (Tredegar, UK).
| Study ethics
The study was approved by the ethics committee at Leuven University Hospital prior to study initiation (EudraCT # 2015-004008-46). All parents/guardians provided written informed consent. The study was conducted in accordance with the ethics and principles of the Declaration of Helsinki and Good Clinical Practice per the ICH Harmonized Tripartite Guideline.
3 | RESULTS
| Demographics and baseline characteristics
Thirteen patients (male = 9, female = 4) aged 11.7 ± 4.4 years (mean ± SD; range = 3-17) were enrolled (Table 1) . In six patients, LGS etiology was identified as either genetic (n = 4) or structural (n = 2; intrauterine toxoplasma and cerebral palsy/lesional epilepsy); the remaining seven cases were of unknown origin. All patients had refractory LGS and a baseline median seizure frequency of 61 per month (range = 21-1360) with multiple seizures types (ie, combinations of tonic, generalized tonic-clonic, myoclonic, absence, and atonic seizures/drop attacks); nine patients reported atonic seizures/drop attacks ( Table 1) . Average patient weight was 45.4 ± 20.2 kg (mean ± SD; range = 16-88 kg). Patients failed a median of five antiepileptic treatments, including VNS and ketogenic diet (range = 3-7); the most frequent treatments failed were levetiracetam (n = 11) and lamotrigine (n = 6). The median treatment duration was 8 years (range = 2-15 years).
At the start of ZX008 administration, patients were currently on a median of four antiepileptic treatments (range = 2-4); the most common therapies were valproate (n = 11), VNS (n = 7), clobazam (n = 5), lamotrigine (n = 5), and rufinamide (n = 4). At 15 months, treatment regimen was comparable to baseline (15 different antiepileptic treatments; median = four per patient, range = 2-4; Table 1 ). All seven patients on VNS at trial initiation had been receiving this treatment for >1 year prior. Ten of 13 enrolled patients completed the core study of 20 weeks of ZX008 treatment (Figure 1 ). Nine patients entered the extension study, two of whom discontinued within 3 months due to lack of efficacy. Seven (78%) patients who entered the extension study were still receiving ZX008 treatment at the time of data extract (15 months).
| Effectiveness
ZX008 therapy resulted in a clinically meaningful reduction in median CS frequency (Figure 2 ). In the core study, the median seizure frequency during the 4-week baseline period was 61 (range = 21-1360, N = 13). A total of four of 13 patients who enrolled in the core study discontinued before entering the extension study due to loss of efficacy (Patient 0101), a combination of lack of efficacy and decreased alertness/sleepiness (Patient 0103), sleep problems (Patient 0105), and decreased alertness (Patient 0111). Patient 0101 was a responder, with 61% reduction in CS frequency until undergoing orthopedic surgery after 12 weeks; the patient remained in the trial until discontinuing at Week 20 without return of a treatment response (Figure 3 ). At the end of the core study, the median seizure frequency for the intent-to-treat study population (N = 13) at last visit was 31 per month (range = 2-890), which was a 53% median reduction in CS frequency. The median seizure frequency in the 10 patients who completed 20 weeks of ZX008 treatment decreased to 22 per month (range = 2-136), which was a 60% median reduction in CS frequency (Figure 2 ). In the core 20-week study, eight of 13 patients (62%) experienced a ≥50% reduction in median CS frequency. Table 2 ). A total of eight of nine (89%) patients who continued into the extension study after 20 weeks were responders during the core study. The one nonresponder (Patient 0109) entered the extension (protocol violation) at the parents' request because the patient's seizures were less severe, but discontinued by Month 3 when meaningful seizure reduction was not achieved. In the extension study, between the last visit and baseline, the median percentage reduction in CS frequency was 58% (n = 9; Table 2 ). A total of six of nine (67%) patients achieved ≥50% median seizure reduction from baseline at 15 months in the extension study; three of nine (33%) patients achieved ≥75% reduction (Table 2) . One patient (0107) was slightly below the responder threshold at 47% CS reduction from baseline but was designated a responder (Figure 3 ; Table 2 ).
In the three nonresponders during the extension study (Patients 0109, 0110, and 0112), seizure frequencies declined initially followed by a gradual return to baseline in Patients 0109 and 0110; Patient 0112 experienced a sharp increase in seizure frequency above baseline by 3 months due to increase in myoclonic seizures (Figure 3) . Patients 0109 and 0112 discontinued within the first 3 months of the extension study due to lack of efficacy. Patient 0112 had substantial loss of appetite, leading to a series of dose reductions (from 0.4 to 0.1 mg/kg/d between Weeks 12 and 16) and subsequent increase in seizure frequency by Month 3 of the extension study. Overall, six of eight (75%) responders at the end of the core study remained responders at 15 months (Figure 3 ).
| Safety
The frequencies of AEs were comparable in the core and extension studies, and the AE profile was comparable across all ZX008 doses. The most common AE was decreased appetite (n = 4), which resolved by 3 months in two patients (Patients 0102 and 0107) who continued in the extension study (Table 3) 
| DISCUSSION
This pilot, open-label study for the treatment of patients with refractory LGS suggests that add-on ZX008 treatment is capable of providing durable, clinically meaningful reduction in CS frequency in a majority of patients, with a tolerable AE profile. Notably, the effect size may be underestimated in the current study because patients who achieved a ≥ 50% reduction in CS frequency had their dose titration stopped rather than continuing titration to achieve maximal efficacy with acceptable tolerability in the core study.
The etiology of LGS is most commonly genetic, symptomatic (ie, secondary to an underlying brain disorder, such as hypoxic-ischemic injury or cerebral malformation), or of unknown cause. 1, 20, 21 The severity and pharmacoresistance of LGS results in an urgent need for developing better F I G U R E 2 Decrease in median seizure frequency in the core (20 weeks) and extension (>20 weeks and up to 15 months) studies after initiating ZX008 in patients with Lennox-Gastaut syndrome. The number of evaluable patients at each time point is shown in parentheses treatment strategies. Because no effective treatment guidelines exist for selecting antiepileptic therapies, therapeutic regimens tend to be individualized, as typified by the heterogeneity of concomitant antiepileptic therapies used by the 13 patients in our study. 1, 3 New treatment options for severe pediatric epilepsies are emerging from recent clinical studies, most notably cannabidiol and ZX008 for the treatment of DS. 7, 22, 23 Cannabidiol (10-20 mg/kg) was found to have efficacy in patients with LGS, with a median reduction of 38% to 45% in drop seizure frequency; 36% to 46% of patients had a ≥50% reduction in seizure frequency. 22, 23 Early case reports suggested anecdotal evidence for the seizure reduction potential of fenfluramine in patients with LGS. 10, 24 As evidence favoring add-on fenfluramine for pharmacoresistant epilepsies accumulated in the 1980s and 1990s, the Belgian government allowed continued use of fenfluramine in a cohort of patients with DS after its withdrawal from the market. 10, 11 Recent results published from
retrospective and prospective open-label studies in the Belgian DS cohort demonstrated profound seizure frequency reduction and durability of effect for up to 28 years of ZX008 treatment without the development of valvulopathy or pulmonary hypertension. [7] [8] [9] These open-label findings were recently confirmed with the report of results from a phase 3 randomized, controlled trial evaluating the use of ZX008 as add-on treatment in patients with DS. For the primary end point of the trial, the 0.8-mg/kg/d dose group experienced a 63.9% greater reduction in CS frequency compared with placebo. 12 Although it is unclear why an orphan drug for the treatment of DS might also be effective in treating patients with LGS, it is possible that the anticonvulsant mechanism of action for fenfluramine is relevant to both DS and LGS. Fenfluramine is metabolized primarily by CYP1A2, CYP2B6, and CYP2D6, with additional metabolism by CYP2C9, CYP2C19, and CYP3A4. 25 Because of the large number of metabolism pathways, it is unlikely that the drugs affecting a single pathway will have a significant potential to affect fenfluramine pharmacokinetics. In vitro drug-drug interaction studies have suggested that both fenfluramine and its active metabolite norfenfluramine may be weak CYP2D6 inhibitors and weak inducers of CYP2B6 and CYP3A4 (Brooks Boyd, written communication, July 2018). In human clinical studies, combination regimens of the antiepileptic drugs stiripentol, clobazam, and valproate increased the exposure of fenfluramine with the expected reduction in its metabolite norfenfluramine, presumably by inhibiting CYP2C19 and CYP3A4, and CYP1A2, CYP2C9, and CYP2D6. [25] [26] [27] [28] The results of these studies suggest that dose adjustments may be needed to maintain therapeutic plasma concentrations of ZX008 in some combination regimens. However, ZX008 did not significantly affect the pharmacokinetics of a triple antiepileptic drug combination regimen consisting of clobazam, valproate, and stiripentol. 25 Additional studies are needed to determine the potential interactions of ZX008 in combination with other antiepileptic drugs that may be used in LGS regimens (ie, lamotrigine, rufinamide, and topiramate). The AE profile in this LGS cohort is consistent with earlier experience in patients with DS. Anorexic effects observed early in treatment resolved within 3 months. A lack of any clinical or echocardiographic findings of cardiac valvulopathy or pulmonary hypertension in this study is consistent with that reported in patients with DS. [7] [8] [9] [10] 12 This study is limited by the small sample size and lack of a placebo control group. Although the exact degree of placebo response cannot be accounted for in the current study, recent open-label experience in DS provided an accurate estimate of the treatment response later observed in a randomized, controlled trial.
7-10,12
| CONCLUSIONS
In conclusion, low-dose ZX008 provided sustained, clinically meaningful CS reduction in a pilot study of patients with refractory LGS who were enrolled in a core study (20 weeks), followed by a long-term extension study (up to 15 months). ZX008 was generally well tolerated with no clinical and/or echocardiographic signs of cardiac valvulopathy or pulmonary hypertension, and may provide a new treatment option in patients with LGS. A phase 3 double-blind, placebo-controlled trial is currently underway to confirm the findings reported in this pilot study. | 1887
